Phase 2Not yet recruiting

Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Infection in United States Adolescents

Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for the Treatment of Helicobacter Pylori Infection in U.S. Adolescents: A Prospective Open-Label Study

Sponsor
Boston Children's Hospital (Academic or other)
Enrollment
55 planned
Conditions
Helicobacter Pylori Infection
Interventions
Vonoprazan; Amoxicillin
Ages
children, adults
Registry
NCT07860112

Full record on ClinicalTrials.gov

From the registry

Helicobacter pylori (H. pylori) is a common bacterial infection of the stomach that can cause chronic stomach inflammation, ulcers, and other digestive problems. The infection is more common among some racial and ethnic minority groups and people from lower-income households, contributing to ongoing health disparities. Current treatment for H. pylori usually requires multiple medications, including antibiotics and acid-suppressing drugs. However, increasing antibiotic resistance has made some standard treatments less effective and can lead to treatment failure. There is a need for simpler, effective treatment options that use fewer antibiotics while maintaining high cure rates. This study will evaluate a treatment consisting of two medications: vonoprazan, an acid-suppressing medication, and amoxicillin, an antibiotic. Vonoprazan provides strong and consistent acid suppression, which may improve the effectiveness of amoxicillin in eliminating H. pylori. Studies in adults and limited studies in children have shown promising results, but this treatment has not been well studied as…

Primary outcomes

  • Helicobacter Pylori Eradication Rate

History

  1. Primary completion expected

  2. Started

  3. Registered